EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

An EV-Guided Multi-Compartment Proof-of-Concept Framework for Biomarker Prioritization in Cholangiocarcinoma

Kanawut Kotawong, Sittiruk Roytrakul, Narumon Phaonakrop, Kesara Na-Bangchang, Wanna Chaijaroenkul

Medical Sciences · 05.03.2026 · 14 (1) · 122

DOI: 10.3390/medsci14010122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Sciences, online erschienen am 05.03.2026. Verfasst von Kanawut Kotawong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Biomarkers, Tumor, Extracellular Vesicles, Bile Duct Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thammasat Postdoctoral Fellowship, Thailand Science Research and Innovation Fundamental Fund, Chulabhorn International College of Medicine and the Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cholangiocarcinoma (CCA) is a highly heterogeneous malignancy in which numerous biomarker candidates have been reported, yet few progress to clinical use. Beyond biological complexity, this low translational yield reflects the lack of systematic criteria for prioritizing biomarkers during the discovery stage. In particular, tumor-derived signals identified in tissue often fail to persist in clinically accessible biofluids, as cross-compartment signal behavior is rarely evaluated explicitly.

Methods

We developed an extracellular vesicle (EV)-guided, multi-compartment proof-of-concept framework to assess biomarker robustness and translatability early in discovery. EV proteomes from three biologically distinct CCA cell lines and a normal cholangiocyte were analyzed using multivariate and machine-learning-assisted approaches to identify conserved EV-associated features. These were integrated with public transcriptomic, epigenetic, copy-number, promoter usage, and miRNA regulatory data. Tissue relevance was assessed using TCGA/GTEx RNA-seq datasets, and exploratory signal behavior was examined in pooled serum- and urine-derived EVs from CCA patients and controls.

Results

EV proteomics revealed marked molecular heterogeneity across CCA models but identified a small subset of conserved EV-associated proteins. SERPINF2 was used as a representative example, showing consistently reduced EV-associated abundance across all CCA models with coordinated regulation across multiple molecular layers. SERPINF2 expression was independent of patient sex and tumor stage and clearly distinguished tumor from normal bile duct tissue. Exploratory biofluid analyses demonstrated compartment-dependent signal behavior, with SERPINF2 depletion detectable in urine-derived EVs but not in serum-derived EVs.

Conclusions

Rather than validating a single biomarker, this study presents an EV-guided, multi-compartment framework for prioritizing biomarker candidates at the discovery stage. By explicitly accounting for tumor heterogeneity and compartment-specific signal preservation, this proof-of-concept approach provides a practical decision-support strategy for identifying biomarkers with greater translational potential in heterogeneous cancers such as CCA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBiomarkers, TumorExtracellular VesiclesBile Duct NeoplasmsHumansCell Line, TumorProteomicsFemaleProof of Concept Study

Stichwörter der Autor:innen

EV proteomicsbiomarker prioritizationcholangiocarcinomaextracellular vesiclesmulti-compartment analysis

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University (Rangsit Campus), 99 Moo 18 Phaholyothin Road, Klong Luang…
  • Functional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathumthani 12120, Thailand.

Förderung

  • Thammasat Postdoctoral Fellowship
  • Thailand Science Research and Innovation Fundamental Fund
  • Chulabhorn International College of Medicine and the Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma
  • National Research Council of Thailand

Zitieren

APA

Kotawong, K., Roytrakul, S., Phaonakrop, N., Na-Bangchang, K., & Chaijaroenkul, W. (2026). An EV-Guided Multi-Compartment Proof-of-Concept Framework for Biomarker Prioritization in Cholangiocarcinoma. Medical Sciences, 14(1), 122. https://doi.org/10.3390/medsci14010122

Vancouver

Kotawong K, Roytrakul S, Phaonakrop N, Na-Bangchang K, Chaijaroenkul W. An EV-Guided Multi-Compartment Proof-of-Concept Framework for Biomarker Prioritization in Cholangiocarcinoma. Medical Sciences. 2026;14(1):122. doi:10.3390/medsci14010122

BibTeX
@article{Kotawong2026,
  author = {Kotawong, Kanawut and Roytrakul, Sittiruk and Phaonakrop, Narumon and Na-Bangchang, Kesara and Chaijaroenkul, Wanna},
  title = {An EV-Guided Multi-Compartment Proof-of-Concept Framework for Biomarker Prioritization in Cholangiocarcinoma},
  journal = {Medical Sciences},
  year = {2026},
  volume = {14},
  number = {1},
  pages = {122},
  doi = {10.3390/medsci14010122}
}
Kostenlos starten →